Pharmaceuticals and Intellectual Property Rights: A Political Economy of the Recent Policy Changes Across the Developing World and in Turkey

Bu makale son yirmi yılda gelişmekte olan ülkeler ve Türkiye de ilaç ürünlerine zayıf koruma sağlayan fikri mülkiyet hakları rejimlerinden güçlü koruma sağlayan rejimlere doğru geçişi içeren siyasa değişikliklerinin sebeplerini irdelemektedir. Bu alandaki siyasa değişikliklerini siyasal iktisat yaklaşımı çerçevesinde inceleyen makale ilaç ürünlerine yönelik fikri mülkiyet rejimlerinde değişime yol açan en önemli sebeplerden birinin uluslarötesi sermayenin özellikle 1980’lerden sonra artan yapısal gücü olduğunu ileri sürmektedir. Siyasa değisikliklerini devletlerarası iktidar ilişkileri çerçevesinde açıklayan devlet merkezli ya da kurumsal teorilerin aksine, makale de ilaç ürünlerine yönelik fikri mülkiyet rejimlerinin şekillenmesinde gelişmekte olan ülkelerdeki sınıf mücadelelerinin dinamiğinin belirleyici olduğu önerilmektedir. Bu önerme makale içerisinde Türkiye de ilaç ürünlerine yönelik fikri mülkiyet hakları rejiminin güçlenmesine yol açan siyasa süreçlerinin ve sonuclarının incelemesi ile desteklenmektedir.

İlaç Ürünleri ve Fikri Mülkiyet Hakları: Gelişmekte Olan Ülkeler ve Türkiye'deki Siyasa Değişikliklerinin Siyasal İktisadı

This paper explores the sources of the recent policy changes from weaker to stronger intellectual property regimes (IPRs) for pharmaceuticals across the developing world, and in Turkey. Analysing the policy change from a political economy approach, the paper argues that the increased structural power of the transnational capital in the 1980s had been the most important common factor in setting the ground for changes in the IPRs for pharmaceuticals across the developing world. Against the state-centric theories that interpret the policy change primarily as a matter between the nation states from developed and developing countries, the paper contends that the nature and scope of policy outcomes on pharmaceutical IPRs have been shaped by the dynamics of the class struggles across the developing world. The latter argument is supported through an analysis of the Turkish public policy processes and outcomes which resulted in strengthening the IPR for pharmaceuticals. The paper concludes that rather than a mere external imposition on the ‘’Turkish state’’ by the advanced capitalist countries or the European Union (EU), the policy change in favour of stronger IPRs for pharmaceuticals was sustained and shaped by the Turkish conglomerate capital which pursued reintegration with the transnational capital as a political strategy.

PDF

___

Ashurst 2005 EU vs US Generics pharmaceuticals regulation Life Sciences Regulatory Update December, downloaded from: www.ashurst.com/ doc.aspx?id_Content=2133
ASSOCIATION COUNCIL DECISION (ACD) No: 1/95 of 6 March 1995) on implementing the Final Phase of Customs Union. Official Journal of European Communities, No: L35, 13.2.1996, pp. 1-46.
ATAY, O., (1992), ‘Ilac ve Patent’ in TEB Haberler , December.
BAKER, B. (2004), The Drug Registraiton Battlefield: US Trade Policy Erects New Nearly Impenetrable Barriers to Lower Cost Generic Medicines of Assured Quality, http://www.cptech.org/ip/health/dataexcl/baker02.16.2004.html.
BALANCE, R. et.al. (1992), The World’s Pharmaceutical Industries: An International Perspective on Innovation Competition and Policy. (Edward Elgar:Hants)
BINA, C. and YAGHMANIAN B. (1990), Post War Global Accumulation and the Transnationalisation of Capital, Review of Radical Political Economics, 22 (1) Spring. 107-130
CAMANOR, W. (1986), “The Political Economy of the Pharmaceutical Industry”, Journal of Economic Literature, XXIV (September 1986), 1178-1217.
CHAUDHURI, S., (1997), “The Evolution of the Indian Pharmaceutical Industry”, Chapter 2 in Felker, G., Chaudhuri, S., and K. Gyorgy, The Pharmaceutical Industry in India and Hungary: Policies, Institutions, and Technological Development. World Bank Technical Paper, 392. (Washington DC:1997) 6-27
CHAUDHURI, S.(1999), Growth and Structural Changes in Pharmaceutical Industry in India. Working Paper Series, Indian Institute of Management Calcutta. WPS-356/99. ————(1984), Manufacturing Drugs Without TNCs: Status of Indigenous Sector in India. Economic and Political Weekly, August, 1341-1383
CHOWDHURY, Z. (1995), The Politics of Essential Drugs. (Zed Books: London)
CHUDNOVSKY (1979), ‘’The Challenge by Domestic Enterprises to the Transnational Corporations’ Domination: A Case Study of the Argentine Pharmaceutical Industry’’ World Development, 7, 45-58
CHUDNOVSKY, D. (1983), ‘’Patents and Trademarks in Pharmaceuticals’’, World Development, 11(3), 187-193.
COHEN, J. (2002), Developing States’ Responses to the Pharmaceutical Imperatives of the TRIPs Agreement, 115-136. Granwille, B.(Ed.) The Economics of Essential Medicines, Plymbridge: London.
CORRERA, C. (1997), The Uruguay Round and Drugs, WHO Action Program on Essential Drugs. ————(2000), Integrating Public Health Concerns into Patent Legislation in Developing Countries. South Centre: Genava. ————(2002), Protection of Data Submitted for the Registration of Pharmaceuticals: Implementing the Standards of the TRIPs Agreement. South Centre: Geneva. Council of Ministers Patent Haklarının Korunması Hakkında Kanun Hükmünde Kararname, KHK/551 27 Haziran 1995 T.C. Resmi Gazete No: 22326.
COUNCIL OF MINISTERS (1995), Patent Haklarinin Korunmasi Hakkinda 551 Sayili Kanun Hukmunde Kararnamede degisiklik yapilmasina Iliskin Kanun Hukmunde Kararname. KHK/566 [Executive Decree Amending the Executive Decree No 551 on Protection of Patent Rights] 22nd September 1995T.C. Resmi Gazete [Official Gazette]. No 22412.
COX, R., (1987), Production, Power and World Order: Social Forces in the Making of History. New York: Colombia Press.
DEMIRDERE, A. (2004), President of the Association for the Research Based Pharmaceutical Companies. Text of the Press Announcement, Anatolian Agency, 9th January, 2004
DIŞ TİCARET MÜSTEŞARLIĞI, T.C. BAŞBAKANLIK (DTM)(1995) Turkiye–AB Iliskileri: Gumruk Birliginin Tamamlanmasina Iliskin 1/95 sayili Turkiye-AB Ortaklik Konseyi Karari; Ortaklik Ilisikilerinin Gelistirilmesine Iliskin Tavsiye Karari, Mali Isbirligi Deklarasyonu,. 6 mart 1995-36. Donem Turkiye AB Ortaklik Konseyi Ankara.
ELLSWORTH, G, P., (1993), “Intellectual Property: The US Concern” in Tavis A.L. & O. Williams.(Eds) The Pharmaceutical Corporate Presence in Developing Countries.
ERCAN, F. (2002), “The Contradictory Continuity of the Turkish Capital Accumulation Process: A Critical Perspective on the Internationalisation of the Turkish Economy” in Balkan, N., S. Savran (eds.) The Ravages of Neoliberalism: economy, society, and gender in Turkey. New York: Nova Science.
EREN, I (2002), The Transnationalisation of the Turkish Pharmaceutical Industry. Unpublished PhD Thesis. University of Sussex, Institute of Development Studies.
EREN-VURAL, I. (2007), “Domestic Contours of Global Regulation: Understanding the Policy Changes on Pharmaceutical Patents in India and Turkey” Review of International Political Economy, 14.1, February .
GEREFFI, G., (1983), The Pharmaceutical Industry and Dependency in the Third World. (Princeton: Princeton University Press).
GILL, R, S. and LAW. D. (1989), ‘Global Hegemony and the Structural Power of the Capital’ International Studies Quarterly. 33, 4, December., 475-499.
GILL, R, S. (1991), American Hegemony, and the Trilateral Commission.
GWYNN, R (1988), ’’Mexico’’ in Gadbaw, R and Micheal T.Richards(Eds.) Intellectual Property Rights: Global Consensus or Global Conflict? Westview Press.
HOLLOWAY, J. (1998), ‘Global Capital and the National State.’ Capital and Class. No: 64
(IEIS) ILAÇ ENDÜSTRİSİ İŞVERENLER SENDİKASI, (2004), Aylık Rapor, No 115, March, 4-5.
IŞIKLI, H. (2005), İlaçlarda test ve deney verilerinin Korunması: AB’de yeni uygulama, İktisadi Sektörler Genel Müdürlüğü, DPT: Ankara.
İSTANBUL HEKİM POSTASI, 2005 ‘’AB’den ilk nota ilaç konusunda geldi’’ No:3, February.
IŞVEREN, (2004), ‘’IEIS’inca hazirlatilan Rapor Ankara da tertiplenen bir toplanti ile tanitildi’’ Ocak,.
KABIRAJ, T. (1995), To Protect or not to Protect Foreign Owned Patents- A Strategic Decision. Institution for Economic Development, Boston University, Economic Discussion Papers Series, No: 60 June.
KÖSEOĞLU, Z. (1994), Globalleşme Sürecinde Türkiyenin Yabancı Sermaye Politikaları. Yabancı Sermaye Genel Müdürlüğü, Ankara.
KIRIM, S, A., (1985a), ‘The Internationalisation of Capital and Industrialisation in Third World: A case Study of the Turkish Pharmaceutical Industry Towards Appraising the Oligopoly Approach to Multinational Corporations’ Unpublished Ph.D. Thesis. Norwich, University of East Anglia. School of Development Studies. ————(1985b), ‘Reconsidering Patents and Economic Development: A case Study of the Turkish Pharmaceutical Industry’, World Development, 13(2), 219-236. ————(1986), ‘The Transnational Corporations and Local Capital: Comparative Conduct and Performance in the Turkish Pharmaceutical Industry’ World Development, 14(4), 503-521.
LA CROIX, S. and KAWAURA, A. (1996), Product Patent Reform and Its Impact on Korea’s Pharmaceutical Industry, International Economic Journal, 10, 1. Spring.
LANJOUW, J. (1997), The Introduction of Pharmaceutical Patents in India: ‘’ Heartless Exploitation of the Poor and Suffering’’ Economic Growth Center Discussion Paper No:775. Yale University.
LIPPERT,O. (2002), A Market Perspective on Recent Developments in the TRIPS and Essential Medicines Debate. In Granville, B.(Ed.) The Economics of Essential Medicines. Plymbridge: London. 3-31
LOVE, J. (2001), ‘’Policies that ensure Access to Medicine, and Promote Innovation’’ Draft Paper presented at the WHO/WTO Joint Secretariat Workshop on Differential Pricing and Financing of Essential Drugs. April 11, 2001, Hobsjor, Norway. Downloaded from www.cptech.org/ip/health/econ/jamie-hobsjor.html
MAXFIELD, S and NOLT, J.N. (1990), ‘Protectionism and the Internationalisation of Capital: US Sponsorship of Import Substitution Industrialisation in the Philippines, Turkey and Argentina’, International Studies Quarterly. 34, 1 March, 49-81.
MAY, C. (2004a), “Capacity building and the (re)production of intellectual property rights”, Third World Quarterly, 25(5), 821-837. ———— (2004b), “Cosmopolitan Legalism Meets Thin Community: Problems in the Global Governance of Intellectual Property”, Government and Opposition. ————(2007), “The Hypocrisy of forgetfulness: The Contemporary Significance of early innovations in Intellectual Property”, Review of International Political Economy, 14(1), 1-25.
MEHROTRA, N.N. (1989), Patents Act and Technological Self Reliance: The Indian Pharmaceutical Industry, Economic and Political Weekly, May 13. 1059-1064.
MOSSINGHOFF, J, G. (1999), “Overview of the Hatch Waxman Act and Its Impact on the Drug Development Process”, Food and Drug Law Journal, 54, 187-194, downloaded from, http://fdli.org/pubs/Journal %20Online/54_2/art2.pdf.
NOGUES, J (1993), ‘’Social Costs and Benefits of Introducing Patent Protection for Pharmaceutical Drugs in Developi ng Countries’’, The Developing Economies, 31(1) March. ————(1990), “Patents and Pharmaceutical Drugs: Understanding the Pressures on Developing Countries”, World Bank Working Paper Series in International Trade, WPS 502
POULANTZAS, N. (2000 (1978)), State, Power, and Socialism. Verso Classics: London First Published 1978. ————(1973), Political Power and Social Classes. New Left Books
PUGATCH, M. P. (2004), “Intellectual Property and Pharmaceutical Data Exclusivity in the Context of Innovation and Market Access” ICTSD-UNCTAD Dialogue on Ensuring Policy Options for Affordable Access to Essential Medicines, Bellagio, 12-16 October.
SAVAŞ, K. (1969), Tıbbi Müstahzarlar Sektörü Hakkında Not. DPT. SPD. Planlama Şubesi. Aralık.
SCHERER, F. M. and WATAL, J. (2002), The Economics of TRIPs Options for Access to Medicines in Granville (Ed.) Granville, B.(Ed.) The Economics of Essential Medicines. Plymbridge: London. 32-56
SELL, S. and MAY, C. (2001), “Moments in Law: contestation and settlement in the history of intellectual property” Review of International Political Economy, 8(3), autumn, 467- 500.
SEQUIERA, K, P. (1998), The Patent System and Technological Development in Late Industrialising Countries: The Case of Spanish Pharmaceutical Industry. Unpublished Ph.D. Thesis submitted to the University of Sussex.
SOUTH CENTRE (1997), The TRIPs Agreement. A guide for the South: The Uruguay Round Agreement on Trade Related Intellectual Property Rights. Genava
STATE PLANNING ORGANISATION (SPO) Annual Plans, Various Issues, Including, 1973, 1975, 1976, 1977, 1978. (SPO: Ankara)
SPO, (1976), Ilac Sanayii Ozel Ihtisas Komisyonu Raporu.
SPO, (1973b), Third Five-Year Development Plan (1973-1977). (SPO: Ankara).
SPO, (1977b), Fourth Five Year Development Plan. Special Committee Report on Pharma-chemicals Industry. (SPO:Ankara)
SPO, (1978b), Fourth Five Year Development Plan. (1978-1983). (SPO: Ankara)
SPO, (1991), Sixth Five Year Development Plan. Special Committee Report on Pharmaceuticals. (SPO: Ankara).
SPO, (2000), Eighth Five Year Development Special Committee Report On Pharmaceutical Industry. (SPO:Ankara)
Suvak, (Saglikta Umut Vakfi) 2003 Ilacta Veri Korumasi, 27 Haziran 2003, Ankara Hilton Oteli, Konferans Cozumlemeleri.
TBMM (1993), Patent Kanunu Tasarısı Görüşmeleri Sanayi, Ticaret ve Teknoloji Komisyonu. Ankara, Türk Tarih Kurumu Basımevi: 1994.
TBMM (1995), Patent Kanunu Tasarısı ile Adalet, Sanayi ve Teknoloji ve Ticaret, Sağlik ve Sosyal İsler, Plan ve Bütçe Komisyonları Raporları (1/495) 19. Dönem , 4. Yasama Yılı.
TURAN, N. (2004), Veri Munhasiriyetinin Sektöre ve Sağlık Harcamalarına Etkisi, Aylık Rapor, IEIS, 2004, Mart , 115, Sayfa: 26-32, ,
TÜM İKTİSATÇILAR BİRLİĞİ (TİB) İlac Dosyası TİB Yayınları No:11. Ankara.
UNIDO (1996), Survey of Selected World Industries. Vienna
UNCTC, (1984), Transnational Corporations in the Pharmaceutical Industry of Developing Countries. (United Nations: New York)
UNITED STATES TRADE REPRESENTATIVE OFFICE (USTR)(1999), ‘’Section 301 Table of Cases ‘’ downloaded from USTR web site, www.ustr.gov/html/act301.htm.
UNITED STATES TRADE REPRESENTATIVE (USTR) (1994), Generalised System of Preferences in National Trade Estimate Annual Report. Downloaded from USTR Office Website: www.ustr.gov/html/1994_gsp.html. ————(1999) Section 301 Table of Cases. Office of USTR.
WATAL, J., and MATHAI, A. P. (1995), Sectoral Impact of the Uruguay Round Agreements on Developing Countries: Pharmaceutical Industry. Global Forum On Industry: Perspectives for 2000 and Beyond. New Delhi. UNIDO.
WATAL, J. (2000), Access to Essential Medicines in Developing Countries: Does the WTO TRIPS Agreement Hinder it? Science Technology and Innovation Discussion Paper No:8 Center for International Development , Harvard University, Cambridge, MA, USA. ————(2001) E-mail correspondence with the author. Date 3. July. 2001, 10:53 A.M.
WINTERS, J, A (1996), Power in Motion: Capital Mobility and the Indonesian State. Cornell University Press: Ithaca
WTO, (2001), Declaration on the TRIPs Agreement and Public Health, Adopted on 14th November 2001, Doha WTO Ministerial, WT/MIN(01)/DEC/2, downloaded from www.wto.org.
YALÇINER ,U. (1999), ‘’Gümrük Birliği ve Türkiye de İlaçta Patent Koruması’’ İktisadi Kalkınma Vakfı Dergisi Ocak-Nisan, No: 143 Stampa, İstanbul. 89-92